CL2018002767A1 - Método para seleccionar proteínas recombinantes ricas en m6p - Google Patents

Método para seleccionar proteínas recombinantes ricas en m6p

Info

Publication number
CL2018002767A1
CL2018002767A1 CL2018002767A CL2018002767A CL2018002767A1 CL 2018002767 A1 CL2018002767 A1 CL 2018002767A1 CL 2018002767 A CL2018002767 A CL 2018002767A CL 2018002767 A CL2018002767 A CL 2018002767A CL 2018002767 A1 CL2018002767 A1 CL 2018002767A1
Authority
CL
Chile
Prior art keywords
lisosomal
proteins
recombinant proteins
recombinant human
proteins rich
Prior art date
Application number
CL2018002767A
Other languages
English (en)
Inventor
Russell Gotschall
Hung V Do
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CL2018002767A1 publication Critical patent/CL2018002767A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Water Supply & Treatment (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MÉTODOS PARA PRODUCIR, CAPTURAR Y PURIFICAR PROTEÍNAS LISOSOMALES HUMANAS RECOMBINANTES. ESTAS PROTEÍNAS LISOSOMALES HUMANAS RECOMBINANTES PUEDEN TENER UN CONTENIDO ELEVADO DE RESIDUOS DE MANOSA-6-FOSFATO. COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTAS PROTEÍNAS LISOSOMALES HUMANAS RECOMBINANTES. MÉTODOS DE TRATAMIENTO. USOS DE ESTAS PROTEÍNAS LISOSOMALES HUMANAS RECOMBINANTES.
CL2018002767A 2016-03-30 2018-09-28 Método para seleccionar proteínas recombinantes ricas en m6p CL2018002767A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662315400P 2016-03-30 2016-03-30
US201762457584P 2017-02-10 2017-02-10
US15/473,994 US10227577B2 (en) 2016-03-30 2017-03-30 Method for selection of high M6P recombinant proteins

Publications (1)

Publication Number Publication Date
CL2018002767A1 true CL2018002767A1 (es) 2019-01-11

Family

ID=58640993

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002767A CL2018002767A1 (es) 2016-03-30 2018-09-28 Método para seleccionar proteínas recombinantes ricas en m6p

Country Status (13)

Country Link
US (3) US10227577B2 (es)
JP (2) JP7046003B2 (es)
KR (3) KR102455821B1 (es)
AU (2) AU2017239640B2 (es)
BR (1) BR112018070189A2 (es)
CA (1) CA3019354A1 (es)
CL (1) CL2018002767A1 (es)
IL (2) IL262060B (es)
MX (3) MX2018011951A (es)
PE (1) PE20190127A1 (es)
SG (1) SG11201808592PA (es)
WO (1) WO2017173059A1 (es)
ZA (2) ZA201807184B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018070189A2 (pt) * 2016-03-30 2019-02-19 Amicus Therapeutics, Inc. método para seleção de proteínas recombinantes ricas em m6p
SG11201808455VA (en) 2016-03-30 2018-10-30 Amicus Therapeutics Inc Formulations comprising recombinant acid alpha-glucosidase
TW201829770A (zh) * 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
DK3624831T3 (da) * 2017-05-15 2023-06-26 Amicus Therapeutics Inc Rekombinant human sur alfa-glucosidase
BR112022004000A2 (pt) * 2019-09-06 2022-05-31 Amicus Therapeutics Inc Método para captura e purificação de biológicas
EP3871687A1 (en) * 2020-02-27 2021-09-01 eleva GmbH Enzyme replacement therapy for treating pompe disease
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
WO2023215865A1 (en) * 2022-05-05 2023-11-09 Amicus Therapeutics, Inc. Methods for treating pompe disease

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US20020073438A1 (en) * 1995-08-02 2002-06-13 Reuser Arnold J. Methods of purifying human acid alpha-glucosidase
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US20020013953A1 (en) * 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
AU753336B2 (en) 1997-11-10 2002-10-17 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
KR20010101131A (ko) 1998-12-07 2001-11-14 추후기재 폼페병의 치료 방법
EP1165080A2 (en) 1999-02-12 2002-01-02 G.D. SEARLE & CO. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
WO2001007078A1 (en) 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
PT3108895T (pt) 2000-07-18 2018-12-18 Univ Duke Tratamento de doenças de armazenanto de glicogénio tipo ii
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP4641705B2 (ja) 2001-04-30 2011-03-02 ザイストール セラピューティクス， インコーポレイテッド 治療的タンパク質の亜細胞標的化
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
BR0213298A (pt) 2001-10-16 2006-11-07 Rxkinetix Inc formulações com alta concentração de proteìna e processo de fabricação
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
ES2686775T3 (es) 2003-01-31 2018-10-19 Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
JP2007523648A (ja) 2004-02-06 2007-08-23 バイオマリン ファーマシューティカル インコーポレイテッド 高リン酸化リソソーム酵素製剤及びそれらの使用
DE602005020745D1 (de) 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP3441090A1 (en) 2005-05-17 2019-02-13 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CA2669347A1 (en) 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
EP2155197A4 (en) 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
EP2150254A4 (en) 2007-04-26 2010-11-10 Amicus Therapeutics Inc DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES
WO2009066069A1 (en) 2007-11-21 2009-05-28 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
HUE051377T2 (hu) 2008-02-12 2021-03-01 Amicus Therapeutics Inc Eljárás betegségek gyógyászati chaperonnal történõ kezelésére adott válasz elõrejelzésére
CA2718182A1 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
MX2010009875A (es) 2008-03-12 2010-11-26 Amicus Therapeutics Inc Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de pompe.
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
US20100119502A1 (en) 2008-11-11 2010-05-13 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
EP2889043B1 (en) 2008-12-16 2019-04-10 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
US8940766B2 (en) 2009-04-09 2015-01-27 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
EP3075386B1 (en) 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011039634A2 (en) * 2009-09-29 2011-04-07 Universiteit Gent Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
US9347050B2 (en) * 2010-09-29 2016-05-24 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
PE20140617A1 (es) 2011-04-22 2014-05-28 Genzyme Corp Alfa glucosidasa acida modificada con procesamiento acelerado
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
US20150258081A1 (en) 2011-12-22 2015-09-17 Centogene Ip Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
WO2013134530A1 (en) 2012-03-07 2013-09-12 Amicus Therapeutics, Inc. High concentration alpha-glucosidase compositions for the treatment of pompe disease
EP3628326B1 (en) 2012-03-15 2024-02-28 Oxyrane UK Limited Methods and materials for treatment of pompe's disease
EP3871688B1 (en) 2012-05-03 2024-03-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
US20150147309A1 (en) 2012-06-06 2015-05-28 Fondazione Telethon Allosteric chaperones and uses thereof
BR112017005810A2 (pt) 2014-09-30 2018-02-27 Amicus Therapeutics Inc alfa-glucosidase ácida altamente potente com carboidratos melhorados
BR112018070189A2 (pt) * 2016-03-30 2019-02-19 Amicus Therapeutics, Inc. método para seleção de proteínas recombinantes ricas em m6p

Also Published As

Publication number Publication date
KR102455821B1 (ko) 2022-10-18
IL262060A (en) 2018-11-29
KR20180128945A (ko) 2018-12-04
SG11201808592PA (en) 2018-10-30
ZA202006604B (en) 2023-04-26
IL295551A (en) 2022-10-01
IL262060B (en) 2022-09-01
KR20210157477A (ko) 2021-12-28
KR20220145918A (ko) 2022-10-31
JP2022101545A (ja) 2022-07-06
BR112018070189A2 (pt) 2019-02-19
JP2019509754A (ja) 2019-04-11
AU2017239640B2 (en) 2022-07-28
US20230079225A1 (en) 2023-03-16
MX2018011951A (es) 2019-02-13
US10227577B2 (en) 2019-03-12
WO2017173059A1 (en) 2017-10-05
ZA201807184B (en) 2021-02-24
CA3019354A1 (en) 2017-10-05
AU2022259797A1 (en) 2022-12-01
MX2022014532A (es) 2022-12-13
MX2022014533A (es) 2022-12-13
US11441138B2 (en) 2022-09-13
JP7436545B2 (ja) 2024-02-21
JP7046003B2 (ja) 2022-04-01
US20170335301A1 (en) 2017-11-23
AU2017239640A1 (en) 2018-10-25
US20190382742A1 (en) 2019-12-19
PE20190127A1 (es) 2019-01-17
KR102343162B1 (ko) 2021-12-23

Similar Documents

Publication Publication Date Title
CL2018002767A1 (es) Método para seleccionar proteínas recombinantes ricas en m6p
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
ES2692773T3 (es) Tratamientos para la fibrosis
EA201792649A1 (ru) Способы кондиционирования пациентов для t-клеточной терапии
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
EA201692098A1 (ru) Биокерамические композиции и их применение для биомодулирования
PE20180260A1 (es) Metodos y kits para tratar la depresion
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
BR112017016772A2 (pt) bactérias probióticas recombinantes para uso no tratamento de uma disfunção inflamatória da pele e método para tratá-la
EA201690898A1 (ru) Способы лечения таупатии
IN2014DE00193A (es)
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
EA201592203A1 (ru) Способы лечения таупатии
EA201792304A1 (ru) Комбинированная терапия для лечения рака
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
EA201791095A1 (ru) Способ лечения рака
MX2018002344A (es) Metodo para tratar el cancer.